AA
CADL icon

AlphaCentric Advisors’s Candel Therapeutics CADL Stock Holding History

AlphaCentric Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
36,683
+370
+1% +$2.79K 0.32% 107
2026
Q1 		$178K Buy
+36,313
New +$198K 0.18% 154

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AlphaCentric Advisors's CADL Position: Q2 2026 in Review

AlphaCentric Advisors increased its Candel Therapeutics (CADL) stake by 1% in Q2 2026, buying an estimated $2.79K and bringing the position to 36,683 shares worth $378K. The position accounts for 0.32% of the portfolio, ranked #107.

AlphaCentric Advisors first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • AlphaCentric Advisors held 36,683 shares of Candel Therapeutics worth $378K as of Q2 2026.
  • AlphaCentric Advisors bought 370 Candel Therapeutics shares in Q2 2026, an estimated $2.79K.
  • Candel Therapeutics made up 0.32% of AlphaCentric Advisors's portfolio in Q2 2026, its #107 holding.
  • AlphaCentric Advisors first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.